Author

V. Tat

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Biochemistry· 1 Cell Biology· 1 Immunology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:host-pathogen & immune response· 5 Organism:mouse· 4 Organism:human· 3 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Drelich· 5 shared C.-T. K. Tseng· 5 shared B.-H. Peng· 3 shared J. Hsu· 3 shared J. Zhu· 3 shared P. Saenkham-Huntsinger· 3 shared C.-T. Tseng· 2 shared P. Huang· 2 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

A. Drelich

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Characterization of Unique Pathological Features of COVID-Associated Coagulopathy: Studies with AC70 hACE2 Transgenic Mice Highly Permissive to SARS-CoV-2 Infection

A. K. Drelich, K. Rayavara, J. Hsu, P. Saenkham-Huntsinger, B. M. Judy, V. Tat, T. G. Ksiazek, B.-H. Peng, C.-T. K. Tseng

This study characterizes the coagulopathy in AC70 hACE2 transgenic mice infected with SARS-CoV-2, revealing hypercoagulable states and ANXA2 system dysregulation.

bioRxiv · Oct 30, 2023Microbiology

Design of SARS-CoV-2 protease inhibitors with improved affinity and reduced sensitivity to mutations

M. Westberg, Y. Su, X. Zou, P. Huang, A. Rustagi, J. Garhyan, P. B. Patel, D. Fernandez, Y. Wu, L. Ning, A. Beck, M. Karim, C. Hao, P. Saenkham-Huntsinger, V. Tat, , M. Z. Lin

This study designs a SARS-CoV-2 protease inhibitor with improved affinity and reduced mutation sensitivity compared to existing drugs.

bioRxiv · Jul 19, 2023 · PreprintMicrobiology

A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta

B. Carter, P. Huang, G. Liu, Y. Liang, P. J. C. Lin, B.-H. Peng, L. McKay, A. Dimitrakakis, J. Hsu, V. Tat, P. Saenkham-Huntsinger, J. Chen, C. Kaseke, G. D. Gaiha, Q. Xu, , D. K. Gifford

A T cell vaccine based on conserved epitopes protects HLA transgenic mice from SARS-CoV-2 Beta variant mortality without inducing neutralizing antibodies.

bioRxiv · Sep 23, 2022Immunology

A bacteriophage-based, highly efficacious, needle and adjuvant-free, mucosal COVID-19 vaccine

J. Zhu, S. Jain, J. Sha, H. Batra, N. Ananthaswamy, P. B. Kilgore, E. Hendrix, Y. M. Hosakote, X. Wu, J. P. Olano, A. Kayode, C. L. Galindo, S. Banga, A. Drelich, V. Tat, , V. B. Rao

This paper develops a bacteriophage-based mucosal vaccine that induces strong immune responses and protects against SARS-CoV-2 and its variants without requiring needles or adjuvants.

bioRxiv · Apr 28, 2022Microbiology

Efficient Neutralization of SARS-CoV-2 Omicron and Other VOCs by a Broad Spectrum Antibody 8G3

H. Ma, C.-T. K. Tseng, H. Zong, Y. Liao, Y. Ke, H. Tang, L. Wang, Z. Wang, Y. He, Y. Chang, S. Wang, A. Drelich, J. Hsu, V. Tat, Y. Yuan, , J. Zhu

This study evaluates the neutralization efficacy of antibodies against SARS-CoV-2 Omicron and other variants, finding that antibody 8G3 maintains broad neutralizing activity while EUA antibodies lose effectiveness.

bioRxiv · Feb 25, 2022 · PreprintCell Biology

The Development of a Novel Nanobody Therapeutic for SARS-CoV-2

G. Ye, J. Gallant, C. Massey, K. Shi, W. Tai, J. Zheng, A. Odle, M. Vickers, J. Shang, Y. Wan, A. Drelich, K. Kempaiah, V. Tat, S. Perlman, L. Du, , F. Li

This paper develops a potent, low-cost nanobody therapeutic, Nanosota-1C-Fc, that effectively blocks SARS-CoV-2 infection in vitro and in vivo with high affinity and stability.

bioRxiv · Nov 17, 2020Microbiology

A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells

D. Mellott, C.-T. Tseng, A. Drelich, P. Fajtova, B. C. Chenna, D. Kostomiris, J. C. Hsu, J. Zhu, Z. Taylor, V. Tat, A. Katzfuss, L. Li, M. A. Giardini, D. Skinner, K. Hirata, , J. H. McKerrow

This paper shows that K777, a cysteine protease inhibitor, blocks SARS-CoV-2 infection by inhibiting host cathepsin L, which is required for spike protein processing, with nanomolar efficacy in several cell lines.

bioRxiv · Oct 23, 2020 · PreprintBiochemistry

FK506-binding protein 13 expression is upregulated in interstitial lung disease and correlated with clinical severity: a potentially protective role.

V. Tat, E. A. Ayaub, A. Ayoub, M. Vierhout, S. Naiel, M. Padwal, S. Abed, O. Mekhael, K. Tandon, S. D. Revill, T. Yousof, P.-S. Bellaye, P. Kolb, A. Dvorkin-Gheva, A. Naqvi, , K. Ask

This study shows FKBP13 is upregulated in interstitial lung diseases and correlates with disease severity, suggesting a protective role against fibrosis.

bioRxiv · Dec 15, 2019Pathology